Optimising Clinical Success With Foundational Heart Failure Treatment

Published: 05 December 2022

  • Views:

    Views Icon 5783
  • Likes:

    Heart Icon 7
  • episode_image
    Now Playing
    Part 1 | Session 1 of 1
    What is GDMT?
    Andrew JS Coats, Mikhail Kosiborod
    Up Next
Average (ratings)
No ratings
Your rating

Overview

This video series is dedicated to the adoption of patient-reported outcomes (PROs) and initiation of guideline-directed medical therapy (GDMT) in daily practice. 

 

In this first discussion, Prof Andrew Coats (Heart Research Institute, Sydney, AU) and Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, Kansas City, US) address how to optimise clinical success using foundational heart failure treatment. 

 

Split into three short videos, Prof Coats and Dr Kosiborod start by summarising current foundational heart failure therapy and how guidance has recently changed across the spectrum of ejection fraction. Following this, they explore recent evidence supporting initiation of GDMT and offer practical advice for the implementation of treatment, including possible solutions to the early uptake of GDMT.

 

Watch the next video in this series 'Personalising Your Approach to Heart Failure Treatment'.

 

 

 

This programme is supported by an unrestricted educational grant from AstraZeneca.

Key Learning Objectives

  • Review current GDMT in HFrEF and HFpEF
  • Describe the relationship between initiation of GDMT and HF outcomes
  • Prescribe GDMT according to current international recommendations

Target Audience

  • Cardiologists
  • Heart Failure Specialists
  • Primary Care Physicians
  • Nurses
  • Pharmacists
  • Other allied HCPs

More from this programme

Part 1

What is GDMT?

In this opening video, Prof Coats and Dr Kosiborod summarise foundational guideline-directed medical therapy (GDMT) across the spectrum of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).

Part 2

Early Initiation and Better Clinical Outcomes

Prof Coats and Dr Kosiborod discuss the relationship between early initiation of foundational GDMT and better clinical outcomes by exploring recent clinical trial data from STRONG-HF.

Part 3

Achieving Early Uptake of GDMT

In this final part, Prof Coats and Dr Kosiborod cover practical approaches for ensuring early optimal GDMT in heart failure, such as, the use of electronic health records and protocols for specific patient subgroups.

Faculty Biographies

Andrew JS Coats

Andrew JS Coats

Professor of Cardiology and Scientific Director

Prof Coats is Editor-in-Chief of the Cardiac Failure Review journal. He has published over 20 patents, more than 750 full research papers and more than 120,000 career citations and has a personal H-index of 146. Andrew was elected to the Presidential Trio of the Heart Failure Association of the ESC in 2018 and will serve as its president from 2020-2022.

Prof Coats is the Immediate past-President of the Heart Failure Association and past-Professor of Cardiology at the University of Warwick, UK. He has also held posts as Head of Cardiology at Imperial College, London and Associate Medical Director and Director of Cardiology at the Royal Brompton and Harefield Hospitals, London. From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine at the University of Sydney.

He is an…

View full profile
Mikhail Kosiborod

Mikhail Kosiborod

Cardiologist

Dr Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.

He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.

Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.

View full profile